Jasper Therapeutics Inc (JSPR) - News Archive

In a significant development for investors in the biotech sector, Pomerantz LLP, a well-regarded law firm known for its dedication to defending shareholder rights, has announced the filing of a class action lawsuit agai...

Investor Alert: A Close Examination of Jasper Therapeutics Amid Securities Class Action Announcement and Competitive Revenue Decline In a significant development for investors of Jasper Therapeutics, Inc. (NASDAQ: JSPR)...

In recent developments, Pomerantz LLP has initiated an investigation into claims on behalf of the investors of Jasper Therapeutics, Inc. (NASDAQ: JSPR), highlighting concerns pertinent to the company’s financial disclos...

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria: A New Hope for Patients Jasper Therapeutics, a pioneering biopharmaceutical company focused on providing tran...

In recent years, the landscape of biotechnology has been enriched by innovative therapeutic approaches aimed at addressing unmet medical needs, particularly in the realm of allergic diseases. Jasper Therapeutics, Inc. (...

In recent months, pharmaceutical company Jasper Therapeutics Inc (NASDAQ: JSPR) has made significant strides in the market, with its shares outperforming the overall market. This article aims to provide an analysis of t...

Jasper Therapeutics Inc Shares Continue to Trail the Market, But Show Promising Signs for InvestorsJasper Therapeutics Inc (NASDAQ: JSPR) has been a source of frustration for investors this year, with its shares underpe...

In recent news, China s domestic investors have shown a lack of confidence in their home markets, leading to extensive outflows of cash into Hong Kong. Simultaneously, Jasper Therapeutics Inc, a clinical-stage biotechno...

Jasper Therapeutics, a prominent clinical stage biotechnology company specializing in the development of briquilimab, has announced the appointment of Dr. Svetlana Lucas, Ph.D., to its esteemed Board of Directors. Dr. L...

Jasper Therapeutics, a leading clinical stage biotechnology company, has recently presented significant preclinical data at the 2024 European Hematology Association (EHA) Hybrid Congress in Madrid, Spain. The data showc...

Jasper Therapeutics Presents Data on Briquilimab in Mast Cell Driven Diseases at EAACI Congress 2024 Jasper Therapeutics, a clinical stage biotechnology company, recently unveiled data on their groundbreaking antibody t...

Jasper Therapeutics, a biotechnology company specializing in the development of briquilimab, a unique antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases, has made significant progress in its research....

Utilizing groundbreaking research and innovative techniques, Jasper Therapeutics, a leading biotechnology company, has recently unveiled positive data on the effectiveness of briquilimab as a conditioning agent in the t...

Jasper Therapeutics Unveils Promising Preclinical Data on Briquilimab at AAAAI Annual MeetingREDWOOD CITY, Calif., Feb. 23, 2024 - Jasper Therapeutics, a leading biotechnology company specializing in the development of...

Jasper Therapeutics to Raise $50 Million in Common Stock Offering for Advancement of Mast-Cell Driven Disease TreatmentsREDWOOD CITY, Calif., Feb. 06, 2024 - Jasper Therapeutics, a clinical-stage biotechnology company d...

:This article highlights the recent preclinical data presentations of briquilimab, a novel antibody therapy developed by Jasper Therapeutics, Inc. The data were presented at the American Academy of Allergy, Asthma, and...

In a recent press release, Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company specializing in the development of briquilimab, announced the issuance of stock options to three new employees. These options...

In a recent press release, Jasper Therapeutics, a prominent biotechnology company specializing in the development of innovative antibody therapy, has announced a significant corporate move. The company will undergo a 1-...